Clinical Trials Directory

Trials / Completed

CompletedNCT04914767

Nigella 5 in the Treatment of SARS COV2 (COVID-19)

The Effectiveness of Nigella Sativa in the Treatment of SARS COV2 (COVID-19)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
500 (actual)
Sponsor
Hôpital Universitaire Sahloul · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet. This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course

Detailed description

In the absence of proven antiviral therapy or specific vaccination against COVID-19, Nigella seed oil is suggested as a potential supplement due to its known immunostimulatory and antiviral activities in previous published studies. Nigella (known as black seed) in the Latin language or "Habatulbarakah" in the Arabic language, is a food supplement and a medicinal plant well known in Arab and Islamic culture. It is used as a food spice and it has a lot of medical claims that come from different historical backgrounds. Nigella seeds contain several active compounds that have been isolated, identified and reported, the most important being thymoquinone. In the literature, black seed has shown several pharmacological activities, including anti-inflammatory, antiviral and immunostimulatory activities.

Conditions

Interventions

TypeNameDescription
DRUGNigellaThe patient will receive a study treatment containing 100 capsules: * One capsule every two hours for the first three days. * From the fourth day, the patient will take one capsule, three times a day for 12 days.
DRUGPlaceboThe patient will receive a study treatment containing 100 capsules: * One capsule every two hours for the first three days. * From the fourth day, the patient will take one capsule, three times a day for 12 days.

Timeline

Start date
2021-03-01
Primary completion
2021-10-30
Completion
2021-12-31
First posted
2021-06-07
Last updated
2022-02-21

Locations

2 sites across 1 country: Tunisia

Source: ClinicalTrials.gov record NCT04914767. Inclusion in this directory is not an endorsement.